Argenx SE (Euronext + Nasdaq: ARGX)

https://www.argen-x.com

argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe auto-immune diseases and cancer. The company is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. argenx’s ability to execute on this focus is enabled by its suite of differentiated technologies. The SIMPLE AntibodyTM Platform, based on the powerful llama immune system, allows argenx to exploit novel and complex targets, and its three complementary Fc engineering technologies are designed to expand the therapeutic index of its product candidates. *

	Start	2019-03-28 renamed before
	Predecessor	Argen-X N.V. (Argenx) (Euronext + Nasdaq: ARGX)
	Industry	therapeutic antibody
	Industry 2	SIMPLE Antibody™ discovery platform
	Person	Van Hauwermeiren, Tim (Argen-X 201101 CEO before Ablynx BusDev Manager before P&G)

	Street	5 Willemstraat
	City	4811 AH Breda
		Address record changed: 2020-12-02

Basic data	Employees	E: 501 to 1,000 (2022-03-01)
	Currency	USD
	Annual sales	539,418,000 (income, operating, consolidated (2021) 2021-12-31)
	Profit	-408,265,000 (2021-12-31)
	Cash	2,336,728,000 (2021-12-31)

		* Document for »About Section«: Argenx SE. (2/28/19). "Press Release: Argenx Reports Fourth Quarter Business Update and Full Year 2018 Financial Results". Breda & Ghent.

		Record changed: 2024-02-12

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Argenx (Argen-X) (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)